Goldman Sachs Research

Equity Research
4 May 2026 | 5:25PM HKT

China SPE: Strong and sustainable growth with attractive valuation; analysis on AMEC/Naura; global WFE model updated

Bottom line: We maintain our positive outlook on China's Semiconductor Production Equipment (SPE) industry, driven by the continuous growth of semis capex in China to build domestic manufacturing capacity. **We conducted a sensitivity analysis** around capex growth and the domestic supply ratio to evaluate the potential upside/downside for key SPE names after the share price hikes YTD. Our analysis suggests that **AMEC and NAURA** have 11% and 5% share price upside, respectively, even in a **bear case**, while in a **bull case**, share prices could increase by 53% and 46% from current valuation levels. We believe the market has not factored in: (1) a potentially stronger capex growth in 2027/28 compared to 2026 due to rising demand from memory and AI-related applications; (2) expanding revenue opportunities from advanced (memory and logic) production lines driven by domestic demand; and (3) higher supply ratios from Chinese vendors due to supply-chain security concerns and cost-saving considerations. **We reiterate our positive view on AMEC (Buy with a 12m TP of Rmb471) and NAURA (Buy with a 12m TP of Rmb638).** Our global semis team raised its WFE estimates to $141/$186/$208 bn in 2026E/27E/28E (read more).

Allen Chang
+852-2978-2930 | allen.k.chang@gs.com
Goldman Sachs (Asia) L.L.C.

Verena Jeng
+852-2978-1681 | verena.jeng@gs.com
Goldman Sachs (Asia) L.L.C.

James Schneider, Ph.D.
+1(212)357-2929 | jim.schneider@gs.com
Goldman Sachs & Co. LLC

Shuhei Nakamura
+81(3)4587-9932 | shuhei.nakamura@gs.com
Goldman Sachs Japan Co., Ltd.

Xuan Zhang
+852-2978-1478 | xuan.zhang@gs.com
Goldman Sachs (Asia) L.L.C.

Ting Song
+852-2978-6466 | ting.song@gs.com
Goldman Sachs (Asia) L.L.C.

Yifan Hu
+852-2978-0996 | yifan.hu@gs.com
Goldman Sachs (Asia) L.L.C.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to www.gs.com/research/hedge.html. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

Exhibit 1: Naura and AMEC both show attractive risk-reward profiles
Implied price (Rmb) and upside/downside (%) from current levels under bear/base/bull scenarios

NAURA

← P/E Multiple \ 2027E EPS →	13.5	15.5	17.5	19.5	21.5
32.5x	438.1	503.1	568.1	633.1	698.1
33.5x	451.6	518.6	585.6	652.6	719.6
34.5x	465.1	534.1	603.1	672.1	741.1
35.5x	478.5	549.5	620.5	691.5	762.5
36.5x	492.0	565.0	638.0	711.0	784.0
37.5x	505.5	580.5	655.5	730.5	805.5
38.5x	519.0	596.0	673.0	750.0	827.0
39.5x	532.5	611.5	690.5	769.5	848.5
40.5x	545.9	626.9	707.9	788.9	869.9

AMEC

← P/E Multiple \ 2027E EPS →	7.1	8.1	9.1	10.1	11.1
47.8x	339.0	386.9	434.7	482.5	530.3
48.8x	346.1	395.0	443.8	492.6	541.4
49.8x	353.2	403.0	452.9	502.7	552.5
50.8x	360.3	411.1	462.0	512.8	563.6
51.8x	367.4	419.2	471.0	522.9	574.7
52.8x	374.5	427.3	480.1	533.0	585.8
53.8x	381.6	435.4	489.2	543.0	596.9
54.8x	388.7	443.5	498.3	553.1	608.0
55.8x	395.8	451.6	507.4	563.2	619.0

Upside/Downside (%)

← P/E Multiple \ 2027E EPS →	13.5	15.5	17.5	19.5	21.5
32.5x	-18%	-6%	6%	18%	30%
33.5x	-16%	-3%	9%	22%	34%
34.5x	-13%	-1%	12%	25%	38%
35.5x	-11%	2%	16%	29%	42%
36.5x	-8%	5%	19%	32%	46%
37.5x	-6%	8%	22%	36%	50%
38.5x	-3%	11%	25%	40%	54%
39.5x	-1%	14%	29%	43%	58%
40.5x	2%	17%	32%	47%	62%

Upside/Downside (%)

← P/E Multiple \ 2027E EPS →	7.1	8.1	9.1	10.1	11.1
47.8x	-10%	3%	16%	28%	41%
48.8x	-8%	5%	18%	31%	44%
49.8x	-6%	7%	20%	34%	47%
50.8x	-4%	9%	23%	36%	50%
51.8x	-2%	11%	25%	39%	53%
52.8x	0%	14%	28%	42%	56%
53.8x	1%	16%	30%	44%	59%
54.8x	3%	18%	32%	47%	62%
55.8x	5%	20%	35%	50%	65%

(1) Orange/ Blue/ Green squares: Bear/ Base/ Bull case; (2) Base case in-line with our 12m TP

Source: Goldman Sachs Global Investment Research

Exhibit 2: WFE spending to earnings power for NAURA and AMEC

	2020	2021	2022	2023	2024	2025	2026E	2027E Bear	2027E Base	2027E Bull	2028E Bear	2028E Base	2028E Bull
Total Semis Capex in China (US$ m)	**25,534**	**32,563**	**33,156**	**34,095**	**40,732**	**42,596**	**44,586**	**44,586**	**44,855**	**48,598**	**44,586**	**45,125**	**52,972**
YoY %		*28%*	*2%*	*3%*	*19%*	*5%*	*5%*	*0%*	*1%*	*9%*	*0%*	*1%*	*9%*
% to WFE	*75%*												
% to Chinese suppliers	*10%*	*12%*	*14%*	*14%*	*17%*	*26%*	*32%*	*35%*	*36%*	*37%*	*39%*	*40%*	*41%*
Total WFE spending in China to Chinese suppliers (US$ m)	**1,965**	**2,994**	**3,546**	**3,681**	**5,242**	**8,202**	**10,593**	**11,704**	**12,162**	**13,486**	**13,041**	**13,589**	**16,289**
YoY %		*52%*	*18%*	*4%*	*42%*	*56%*	*29%*	*10%*	*15%*	*27%*	*11%*	*12%*	*21%*

Naura	C20	C21	C22	C23	C24	C25	C26E	2027E Bear	2027E Base	2027E Bull	2028E Bear	2028E Base	2028E Bull
Revenue (Rmb)	**6,056**	**9,683**	**14,688**	**22,079**	**29,838**	**39,353**	**51,163**	**59,580**	**63,056**	**73,087**	**71,264**	**75,752**	**99,153**
YoY		*60%*	*52%*	*50%*	*35%*	*32%*	*30%*	*16%*	*23%*	*43%*	*20%*	*20%*	*36%*
Beta x WFE		*1.1x*	*2.8x*	*13.2x*	*0.8x*	*0.6x*	*1.0x*	*1.57x*	*1.57x*	*1.57x*	*1.72x*	*1.72x*	*1.72x*
Diluted EPS (Rmb)	**0.81**	**1.59**	**3.30**	**5.43**	**7.83**	**7.64**	**10.56**	**15.46**	**17.48**	**23.32**	**18.88**	**21.46**	**32.71**
YoY		*96%*	*107%*	*65%*	*44%*	*-2%*	*38%*	*46%*	*66%*	*121%*	*22%*	*23%*	*40%*
EPS leverage		*1.6x*	*2.1x*	*1.3x*	*1.3x*	*-0.1x*	*1.3x*	*2.8x*	*2.8x*	*2.8x*	*1.1x*	*1.1x*	*1.1x*

AMEC	C20	C21	C22	C23	C24	C25	C26E	2027E Bear	2027E Base	2027E Bull	2028E Bear	2028E Base	2028E Bull
Revenue (Rmb)	**2,273**	**3,108**	**4,740**	**6,264**	**9,065**	**12,385**	**16,931**	**20,540**	**22,031**	**26,333**	**25,362**	**27,341**	**37,574**
YoY		*37%*	*52%*	*32%*	*45%*	*37%*	*37%*	*21%*	*30%*	*56%*	*23%*	*24%*	*43%*
Beta x WFE		*0.7x*	*2.8x*	*8.4x*	*1.1x*	*0.6x*	*1.3x*	*2.03x*	*2.03x*	*2.03x*	*2.05x*	*2.05x*	*2.05x*
Diluted EPS (Rmb)	**0.92**	**1.76**	**1.90**	**2.88**	**2.60**	**3.37**	**6.47**	**8.32**	**9.09**	**11.30**	**10.77**	**11.83**	**17.33**
YoY		*91%*	*8%*	*52%*	*-10%*	*30%*	*92%*	*29%*	*40%*	*74%*	*29%*	*30%*	*53%*
EPS leverage		*2.5x*	*0.2x*	*1.6x*	*-0.2x*	*0.8x*	*2.5x*	*1.3x*	*1.3x*	*1.3x*	*1.3x*	*1.3x*	*1.3x*


Base case revenue and EPS are consistent with our latest published estimates

Source: Company data, Goldman Sachs Global Investment Research

We conducted a sensitivity analysis of Chinese SPE vendors by linking: (1) semiconductor capex to the WFE revenues of Chinese suppliers, then to: (2) the earnings power of NAURA and AMEC, and finally to: (3) current equity valuations to assess the relative risk/reward. **Our analysis is as follows:**

1. Our base case forecasts for **China semiconductor capex** imply 5%/ 1%/ 1% growth for 2026-28E (read more in our China semis thematic report). However, we see upside (our bull case suggests 5%/ 9%/ 9% YoY capex growth in 2026-28E) if the growing demand from AI devices/ AI data centers, the memory supply gap, recovering industrial demands, and more advanced node capacity expansions are better than our base case and downside (our bear case suggests 5%/ 0%/ 0% YoY growth) if demand weakens due to depressed consumer demand and tighter constraints of overseas equipment supply.
2. **Domestic companies** are expected to account for 32%/ 36%/ 40% of the China WFE market in 2026-28E in our base case, with 32%/ 35%/ 39% in our bear case and 32%/ 37%/ 41% in our bull case.
3. **Bull-case 2027 EPS** are Rmb11.30 / Rmb23.32 (+74% YoY / +121% YoY) for AMEC / NAURA; **Bear-case 2027 EPS** are Rmb8.32 / Rmb15.46 (+29% YoY / +46% YoY). Base-case EPS for 2027 is consistent with our last publication at Rmb9.09/ Rmb17.48 (+40% YoY/ +66% YoY) for AMEC and NAURA.
4. Using 51.8x / 36.5x P/E for AMEC / NAURA, consistent with the multiples implied by our target prices for the two companies, we see **11%/ 5% price upsides even in our bear cases**. Accordingly, we believe the current valuations are attractive.

Exhibit 3: Semis capital expenditures in China: We expect them to remain high at US$43-46bn in 2025-30E



Compared to our last update in Oct-24, we raised our 2025-30E capex by 6%/ 6%/ 2%/ 3%/ 3%/ 4%

Source: Company data, Goldman Sachs Global Investment Research

Exhibit 4: Expanding product coverage of SPE suppliers in China
Green highlights denote new products announced after Oct 2024

	Ticker	002371.SZ	688012.SS	ACMR	688037.SS	688072.SS	600641.SS	Private	688729.SS	688120.SS	688361.SS	300567.SZ	Private	688200.SS	New product launch
Thermal process	Oxidation / Diffusion	✓ (14nm)		✓ Matured				✓							
	Annealing	✓ (14nm)		✓ Matured				✓	✓						
	Rapid thermal processing	✓ (14nm)					✓ Matured	✓	✓						
Lithography	DUV												✓ Matured		
	Immersion DUV														
	EUV														
Etcher	CCP	✓	✓ (5nm)				✓ Matured	✓ Advanced							
	Double Damascus CCP	✓						✓ Advanced							
	High Aspect Ratio	✓ (50:1)	✓ (90:1 in R&D)					✓ Advanced							2025: AMEC expect to deliver 90:1 high aspect ratio CCP to clients
	ICP	✓ (7nm)	✓				✓ Matured	✓	✓						
	TSV	✓ (14nm)	✓												
	Bevel etch	✓	✓												2025: AMEC announced the upgraded wafer bevel etch equipment Primo Halona
	ALE	✓													
Photoresist	Coater/ Developer	✓* (Kingsemi)		Evaluation (KrF, 2025)	✓ (28nm)										2025: AMEC's KrF Track sample model entered customer evaluation
	Stripper	✓* (Kingsemi)		✓	✓ (28nm)				✓						
CVD	LPCVD	✓ (14nm)	✓ Advanced	✓											2022-23: AMEC developed LPCVD tools, achieved first sales in 2024
	PECVD	✓	Evaluation (2022)	Evaluation (2024)		Evaluation (14nm)	✓ Matured	✓							2022: ACMR delivered its first PECVD tool
	EPI	✓	Evaluation (2024)					✓							2024: AMEC's EPI CVD tool is in customer evaluation
	SACVD					✓ (28nm)	✓ Matured								2022-23: Wanye won new client orders on MOCVD and SACVD tools
	HDPCVD	Evaluation (2024)				✓	✓ Matured								2024: NAURA HDPCVD entered client production line
	Flowable CVD					✓									2024: Piotech's FCVD pass customer evaluation
	MOCVD	✓	✓				✓ Matured								2022-23: Wanye won new client orders on MOCVD and SACVD tools
	Tube CVD	✓		✓											
ALD	PEALD		✓	Evaluation (2024)		✓ (14nm)		✓							2022-23: AMEC launched ALD tools **2024: ACMR launched PEALD tools**
	Thermal ALD	✓ (14nm)		✓		Evaluation (2024)		✓							2022-23: Piotech launched thermal ALD 2022: ACMR launched thermal ALD
PVD	AI-Pad	✓ (14nm)	R&D (2025-29)				✓ Matured	✓							**2025: AMEC started R&D of PVD**
	Hard mask	✓ (14nm)						✓							2022-23: Wanye won new client orders on PVD tools (AI PAD, CuBS)
	CuBS	(14nm)					✓ Matured	✓							
Ion Implanter	High energy						✓ (28nm)			R&D					**2025: Naura announced the first Ion implanter**
	High current	Announced (2025)					✓ (28nm)			✓ Advanced					
	Medium/ low current														
CMP	CMP									✓ (14nm)					
Cleaning tool	Single wafer	✓ (14nm)		✓	Evaluation (14nm, 2024)					✓					2024: Kingsemi launched new single wafer cleaning tool
	Batch	✓ (28nm)		✓											2024: Hwatsing expects revenues from cleaning tool
ECP	Electroplating	Announced		✓											**2025: Naura announced its first 12" ECP equipment**
Inspection	Bright field pattern wafer		✓ Raintree					✓			Evaluation (2024)	✓ (14nm)			2024: Skyverse's bright field pattern wafer tool is in customer evaluation
	Dark field pattern wafer							✓			Evaluation (2024)	R&D			2024: Skyverse's dark field pattern wafer tool is in customer evaluation
	Unpatented wafer							✓			✓ Matured	✓ Advanced			
	Patterned wafer										✓ Matured				
Metrology	Optical critical dimension (OCD)		✓ Raintree								✓ Matured	✓ Advanced			
	CDSEM		R&D (2025)									✓ Advanced			**2025:** AMEC announced to penetrate to the process control market
	Overlay accuracy							✓			✓ Matured				
	Dielectric thin-film		✓ Raintree									✓ Advanced			
	Metal thin-film		✓ Raintree								✓ Matured	✓ Advanced			
	3D Metrology										✓ Matured				
Back-end															
Testing	Analog													✓	
	SoC													Evaluation (2024)	2023: Accotest launched STS8600 tester
	Power							✓						✓	
Die bonder	Traditional				✓ (Temp bonding)										
	TCB														
	Hybrid bonding					✓									

* Naura acquired Kingsemi in 2025; Data source of SMEE:
http://www.smee.com.cn/eis.pub?service=homepageService&method=indexinfo&onclicknodeno=1_4_1_1

Source: Company data, Data compiled by Goldman Sachs Global Investment Research

AMEC (Buy)

We are positive on AMEC's expansion towards comprehensive product offerings across etching, deposition, metrology, and CMP tools, along with a product mix upgrade towards fulfilling rising spending on advanced nodes. During SEMICON (report link), AMEC launched its new ICP etcher, high selectivity etchers, and Micro LED MOCVD tools with enhanced performance. The company also announced its plans to acquire 64.69% shares of CMP supplier Hangzhou Sizonetech. We believe AMEC will continue to outgrow the industry given its high exposure to memory customers and rapid production expansions.

Investment Thesis - AMEC

AMEC is a key supplier of etching equipment and metal-organic chemical vapor deposition (MOCVD) equipment. The company has also been expanding its product line-up with the near-term focus on: 1) CCP etchers for dual-damascene process in advanced nodes and high aspect ratio process in memory, and 2) ICP etcher for advanced nodes and dual-station product - Twinstar. In the longer term, AMEC is also expanding into Epi tools and LPCVD tools. We are Buy-rated on AMEC, expecting the company to enjoy solid growth on the back of product line expansion, clients' continuous capacity expansions, and growing adoption of domestic equipment. The company is now trading below its historical average 12M forward P/E, implying an attractive valuation.

Price Target Risks and Methodology - AMEC

Valuation: Our 12-month target price of Rmb471 is based on 43.8x 2029E P/E, discounted back to 2026E at COE of 11%. Our target multiple is based on its long-term EPS growth compared to global peers' P/E vs. EPS growth correlation.

Key downside risks: (1) Current trade restrictions do not specifically target matured node fabs, but if restrictions were to expand to matured nodes, it would further reduce demand for AMEC's products. (2) AMEC supplies etchers that can be used for 5nm production lines overseas (i.e., advanced nodes); if its ability to supply such products is hindered, it could lead to further downside risks. (3) Weaker-than-expected capex of major foundries in China.

Naura (Buy)

We are positive on NAURA as a leading local SPE platform provider. The company has accelerated its R&D roadmap to invest in enhanced tools for advanced-node clients. Additional product lines are being developed to offer comprehensive coverage across thermal processes, deposition, etching, cleaning, and ion implantation. Despite elevated near-term R&D spending, we expect sustained growth momentum in both top-line revenue and market share.

Investment Thesis - NAURA

NAURA is a key local SPE maker with diversified end-markets and product offerings across thermal process, deposition, and silicon etching, and cleaning tools for semiconductor fabs. We are Buy rated on NAURA, mainly because of its leading market position and comprehensive offerings, which enables NAURA to ride on local semis capacity expansion in mature nodes. We expect: 1) strong China semis capex given

stronger-than-expected 2024 guidance due to local foundries' and IDMs' capacity expansion in mature nodes; (2) NAURA's improved contract liability to revenues ratio to support 2024 revenue growth; and (3) better operating efficiency for NAURA under its rising revenue scale. The stock is trading at the lower end of its historical trading range, which we find attractive as well.

Price Target Risks and Methodology - NAURA

Valuation: We are Buy rated on NAURA with a 12-month target price of Rmb638, which is based on a 36.5x 2027E P/E. Our target P/E is derived from global SPEs' regression of P/E and forward year earnings growth.

Key downside risks: 1) Further US export restrictions on China semiconductor firms, which could delay their capacity expansion schedule and therefore reduce the demand for NAURA's equipment; 2) Slower-than-expected capacity expansion progress at NAURA's matured nodes customers, which could lead to slower revenue growth than we expect and therefore lower earnings vs. our current estimates.

Disclosure Appendix

Reg AC

We, Allen Chang, Verena Jeng, James Schneider, Ph.D., Shuhei Nakamura, Xuan Zhang, Ting Song and Yifan Hu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

Contributing Authors: Allen Chang Goldman Sachs (Asia) L.L.C., Verena Jeng Goldman Sachs (Asia) L.L.C., James Schneider, Ph.D. Goldman Sachs & Co. LLC, Shuhei Nakamura Goldman Sachs Japan Co., Ltd., Xuan Zhang Goldman Sachs (Asia) L.L.C., Ting Song Goldman Sachs (Asia) L.L.C., Yifan Hu Goldman Sachs (Asia) L.L.C..

Unless otherwise stated, the individuals listed in the Contributing Authors disclosure of this report are analysts in Goldman Sachs' Global Investment Research division.

GS Factor Profile

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our universe of rated stocks) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

Growth is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile and (100% - Multiple percentile).

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

M&A Rank

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

Disclosures

Logo disclosures

Third party brands used in this report are the property of their respective owners, and are used here for informational purposes only. The use of such brands should not be viewed as an endorsement, affiliation or sponsorship by or for Goldman Sachs or any of its products/services.

Rating and pricing information

AMEC (Buy, Rmb376.30) and NAURA (Buy, Rmb536.99)

The rating(s) for AMEC and NAURA is/are relative to the other companies in its/their coverage universe: AAC, ACM Research, AMEC, ASMPT, AVC, AccoTest, Anji Micro, Asus, Auras, BOE, BYDE, Biren, CR Micro, Cambricon, Chenbro, China Mobile (HK), China Telecom, China Tower Corp., China Unicom, Chinasoft Intl, Compal, Desay SV, E Ink, E-Town Semis, EHang, Empyrean, Eoptolink, Fositek, Foxconn Industrial Internet, Gigabyte, Gigadevice, Glodon Co., HTC Corp., Hikvision, Hon Hai, Horizon Robotics, Hua Hong, Hwatsing, Innolight, Inspur, Insta360, Inventec, JCET, Kematek, King Slide, Kingdee, Kingsoft Office, LandMark, Largan, Lenovo, Lingyi, Luxshare, Maxscend, Meitu, MetaX, Mitac, Montage (A), Montage (H), NAURA, NSIG, Nexchip, OmniVision, Pegatron, Pony AI Inc. (ADR), Pony AI Inc. (H), Quanta, RoboTechnik, Ruijie Networks, SG Micro, SICC, SMIC (A), SMIC (H), SZS, Sangfor, SenseTime, Shengyi Tech, Shennan Circuits, StarPower, Sunny Optical, TFC Optical, Thundersoft, Transsion, UMT, UNIS, VPEC, Vanchip, VeriSilicon, Victory Giant, WNC, WUS, WeRide, Wistron, Wiwynn, YJ Semitech, YOFC, Yonyou, ZTE (A), ZTE (H), iFlytek

Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by Goldman Sachs Global Investment Research and referred to in this research.

Goldman Sachs beneficially owned 1% or more of common equity (excluding positions managed by affiliates and business units not required to be aggregated under US securities law) as of the second most recent month end: AMEC (Rmb376.30) and NAURA (Rmb536.99)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: AMEC (Rmb376.30)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: AMEC (Rmb376.30)


Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global Equity coverage universe


	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	50%	34%	16%	65%	60%	45%

As of April 1, 2026, Goldman Sachs Global Investment Research had investment ratings on 3,074 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

Target price history table(s)

NAURA (002371.SZ)

Date of report	Target price (Rmb)	Closing price (Rmb)
30-Apr-26	638.00	536.99
21-Apr-26	600.00	450.36
01-Nov-25	572.00	407.05
24-Sep-25	561.00	460.68
29-Aug-25	492.00	372.50
28-Apr-25	597.00	336.61
14-Jan-25	540.00	289.89
14-Nov-24	576.00	332.82
14-Oct-24	503.00	273.34
09-Oct-24	502.00	300.00
11-Sep-24	438.00	222.56
11-Jul-24	432.00	232.05
29-Apr-24	428.00	239.26
25-Mar-24	379.00	234.67
15-Jan-24	334.00	171.84
07-Dec-23	315.00	160.39
31-Oct-23	294.00	189.63
13-Oct-23	310.00	184.22
29-Aug-23	307.00	193.64
16-Jul-23	344.00	221.41
14-Jun-23	340.00	234.52

AMEC (688012.SS)

Date of report	Target price (Rmb)	Closing price (Rmb)
28-Apr-26	471.00	362.27
04-Apr-26	462.00	293.50
06-Jan-26	459.00	329.67
22-Dec-25	424.00	272.72
30-Oct-25	423.00	300.04
26-Sep-25	386.00	290.00
23-Sep-25	340.00	280.00
29-Aug-25	299.00	214.17
18-Jul-25	266.00	182.25
11-Mar-25	275.00	204.70
15-Jan-25	214.70	186.39
13-Nov-24	200.70	242.50
14-Mar-24	177.00	151.49
27-Oct-23	176.00	165.56
14-Oct-23	165.00	162.82
24-Aug-23	158.00	133.80
17-Jul-23	167.00	139.80
14-Jun-23	169.00	164.86

Price targets shown in table(s) are unadjusted for corporate actions.

Regulatory disclosures

Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts,

professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with a subject company, public appearances and trading in securities covered by the analysts.

Distribution of ratings: See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at https://www.gs.com/research/hedge.html.

Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of Global Investment Research of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Brazil:** Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 10th Floor, Ascent-Worli, Sudam Kalu Ahire Marg, Worli, Mumbai-400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Goldman Sachs (India) Securities Private Limited compliance officer and investor grievance contact details can be found at: https://www.goldmansachs.com/worldwide/india/documents/Grievance-Redressal-and-Escalation-Matrix.pdf, and a copy of the annual audit compliance report can be found at this link: https://publishing.gs.com/content/site/india-annual-compliance-report.html. **Japan:** See below. **Korea:** This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **New Zealand:** Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. **Russia:** Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

European Union and United Kingdom: Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at https://www.gs.com/disclosures/europeanpolicy.html which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan Type II Financial Instruments Firms Association, and Investment Management Association of Japan. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Early-Stage Biotech, Coverage Suspended or Not Covered), is deemed Neutral. Each region manages Regional Conviction Lists, which are selected from Buy rated stocks on the respective region's Investment Lists

and represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction Lists are managed by the Investment Review Committee or other designated committee in each respective region and do not represent a change in the analysts' investment rating for such stocks.

Total return potential represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) are removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. **Early-Stage Biotech (ES).** An investment rating and a target price are not assigned pursuant to Goldman Sachs policy when this company has neither a drug, treatment or medical device that has passed a Phase II clinical trial nor a license to distribute a post-Phase II drug, treatment or medical device. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company.

Global product; distributing entities

Goldman Sachs Global Investment Research produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h às 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

European Economic Area: Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research within the European Economic Area.

General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by Global Investment Research. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (https://www.sipc.org).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research, unless otherwise prohibited by regulation or Goldman Sachs policy.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at https://www.theocc.com/about/publications/character-risks.jsp and https://www.goldmansachs.com/disclosures/cftc_fcm_disclosures. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be

supplied upon request.

Differing Levels of Service provided by Global Investment Research: The level and types of services provided to you by Goldman Sachs Global Investment Research may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to https://research.gs.com.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

© 2026 Goldman Sachs.

You are permitted to store, display, analyze, modify, reformat, and print the information made available to you via this service only for your own use. You may not resell or reverse engineer this information to calculate or develop any index for disclosure and/or marketing or create any other derivative works or commercial product(s), data or offering(s) without the express written consent of Goldman Sachs. You are not permitted to publish, transmit, or otherwise reproduce this information, in whole or in part, in any format to any third party without the express written consent of Goldman Sachs. This foregoing restriction includes, without limitation, using, extracting, downloading or retrieving this information, in whole or in part, to train or finetune a machine learning or artificial intelligence system, or to provide or reproduce this information, in whole or in part, as a prompt or input to any such system.